Getinge (DB:GTN) - Aandelenkoers, Nieuws & Analyse

GTN Overzicht aandelen

Getinge AB (publ) levert producten en oplossingen voor operatiekamers, intensive-care-units en sterilisatieafdelingen.

GTN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

Verhandeld tegen 46.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 12.22% per jaar groeien

Risicoanalyse

Onstabiel dividend track record

Winstmarges (5%) zijn lager dan vorig jaar (7.4%)

Getinge AB (publ) Concurrenten

Carl Zeiss Meditec

XTRA:AFX

€5.8b

Eckert & Ziegler

XTRA:EUZ

€926.4m

Drägerwerk KGaA

XTRA:DRW3

€834.8m

Siemens Healthineers

XTRA:SHL

€58.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Getinge
Historische aandelenkoersen
Huidige aandelenkoers	SEK 18.12
52 Week Hoogtepunt	SEK 20.85
52 Week Laag	SEK 15.60
Bèta	0.47
11 maand verandering	-8.60%
3 maanden verandering	4.89%
1 Jaar Verandering	16.15%
33 jaar verandering	-55.79%
5 jaar verandering	24.62%
Verandering sinds IPO	66.24%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	GTN	DE Medical Equipment	DE Markt
7D	-2.1%	-0.6%	1.0%
1Y	16.2%	10.5%	19.0%

Rendement versus industrie: GTN overtrof de German Medical Equipment industrie, die het afgelopen jaar een rendement 6.1 % opleverde.

Rendement versus markt: GTN presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 12.5 % opleverde.

Prijsvolatiliteit

Is GTN's price volatile compared to industry and market?
GTN volatility
GTN Average Weekly Movement	3.1%
Medical Equipment Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: GTN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van GTN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1904	11,848	Mattias Perjos	www.getinge.com

Getinge AB (publ) levert producten en oplossingen voor operatiekamers, intensive-care-units en sterilisatieafdelingen. Het bedrijf opereert via de segmenten Acute Care Therapies, Life Science en Surgical Workflows. Het bedrijf biedt extracorporale membraanoxygenatie, mechanische beademing, mechanische circulatieondersteuning, geavanceerde patiëntbewaking, ICU-infrastructuurapparatuur, patiëntenstroombeheer en drainageoplossingen.

Getinge AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Getinge zich tot de beurswaarde?
GTN fundamentele statistieken
Marktkapitalisatie	€4.74b
Inkomsten(TTM)	€147.84m
Inkomsten(TTM)	€2.94b

32.1x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is GTN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GTN resultatenrekening (TTM)
Inkomsten	SEK 33.59b
Kosten van inkomsten	SEK 18.21b
Brutowinst	SEK 15.39b
Overige uitgaven	SEK 13.69b
Inkomsten	SEK 1.69b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Jan 28, 2025

Winst per aandeel (EPS)	6.21
Brutomarge	45.80%
Nettowinstmarge	5.03%
Schuld/Eigen Vermogen Verhouding	30.0%

Hoe presteerde GTN op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.2%

Huidig dividendrendement

71%

Uitbetalingsratio

GTN Overzicht aandelen

Beloningen

Risicoanalyse

Getinge AB (publ) Concurrenten

XTRA:AFX

€5.8b

XTRA:EUZ

€926.4m

XTRA:DRW3

€834.8m

XTRA:SHL

€58.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)

Independent Director recently bought €98k worth of stock

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought €375k worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)

Recent updates

Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)

Independent Director recently bought €98k worth of stock

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought €375k worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)

New minor risk - Share price stability

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Investor sentiment deteriorates as stock falls 17%

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Dividend of kr4.40 announced

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Third quarter 2023 earnings released

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Second quarter 2023 earnings released

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Investor sentiment deteriorates as stock falls 16%

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

First quarter 2023 earnings released

Now 23% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Investor sentiment deteriorated over the past week

Getinge Revises Net Sales Guidance for the Full Year 2022

Independent Chairman recently bought €281k worth of stock

Insufficient new directors

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Upcoming dividend of kr4.00 per share

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)

Insufficient new directors

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Chief Commercial Officer recently bought €56k worth of stock

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020)